We are live on ! Find out more
PCVX icon

Vaxcyte
PCVX

251 hedge funds and large institutions have $8.13B invested in Vaxcyte in 2024 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 102 increasing their positions, 77 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 18

37% more call options, than puts

Call options by funds: $16.7M | Put options by funds: $12.2M

32% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 77

25% more capital invested

Capital invested by funds: $6.51B → $8.13B (+$1.63B)

13% more funds holding

Funds holding: 223 → 251 (+28)

0.97% more ownership

Funds ownership: 108.91% → 109.87% (+0.97%)

14% less funds holding in top 10

Funds holding in top 10: 14 → 12 (-2)

Holders
251
Holders Change
+28
Holders Change %
+12.56%
% of All Funds
3.62%
Holding in Top 10
12
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-14.29%
% of All Funds
0.17%
New
48
Increased
102
Reduced
77
Closed
18
Calls
$16.7M
Puts
$12.2M
Net Calls
+$4.53M
Net Calls Change
-$2.42M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$160M
2
DGM
Darwin Global Management
Jersey
+$150M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$142M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$89M
5
PBA
Paradigm Biocapital Advisors
New York
+$85.9M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$40.5M
2
Millennium Management
Millennium Management
New York
-$33.5M
3
VPC
Vestal Point Capital
New York
-$33M
4
GPP
Great Point Partners
Connecticut
-$22.6M
5
Pictet Asset Management
Pictet Asset Management
Switzerland
-$19.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$1.11B +$142M +2,047,794 +14%
Vanguard Group
2
Vanguard Group
Pennsylvania
$665M +$89M +1,284,883 +15%
BlackRock
3
BlackRock
New York
$650M +$64.9M +937,160 +11%
RCM
4
RA Capital Management
Massachusetts
$560M +$21.6M +312,500 +4%
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$524M +$48M +692,492 +10%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$336M +$33.8M +487,450 +11%
Capital Research Global Investors
7
Capital Research Global Investors
California
$283M +$48.5M +700,414 +20%
T. Rowe Price Investment Management
8
T. Rowe Price Investment Management
Maryland
$243M +$160M +2,306,926 +185%
State Street
9
State Street
Massachusetts
$228M -$3.63M -52,436 -2%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$217M +$34.5M +498,359 +19%
DGM
11
Darwin Global Management
Jersey
$188M +$150M +2,170,845 +374%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$156M +$21.7M +313,869 +16%
Franklin Resources
13
Franklin Resources
California
$147M +$74.1M +1,070,736 +99%
PA
14
Perceptive Advisors
New York
$132M +$58.5M +844,273 +78%
DCM
15
Driehaus Capital Management
Illinois
$128M +$13.4M +193,439 +12%
AllianceBernstein
16
AllianceBernstein
Tennessee
$122M -$9.3M -134,344 -7%
Westfield Capital Management
17
Westfield Capital Management
Massachusetts
$108M +$9.04M +130,502 +9%
FAM
18
Fred Alger Management
New York
$95.4M -$18.9M -273,478 -16%
Jennison Associates
19
Jennison Associates
New York
$85.9M -$15.2M -219,271 -15%
PBA
20
Paradigm Biocapital Advisors
New York
$84.7M +$85.9M +1,239,995 New
Invesco
21
Invesco
Georgia
$84.3M +$69.8M +1,007,558 +444%
B
22
Braidwell
Connecticut
$82.8M -$5.35M -77,262 -6%
JP Morgan Chase
23
JP Morgan Chase
New York
$79.4M +$52.4M +756,443 +187%
FLSM
24
Frazier Life Sciences Management
California
$77.8M -$1.73M -25,000 -2%
O
25
OrbiMed
New York
$72.8M -$6.02M -86,960 -8%
1
2 3 4 5

PCVX Hedge Fund Activity: Q1 2024 in Review

251 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2024, worth a combined $8.13B — up 25% from $6.51B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new PCVX positions and 18 closed out — a net gain of 30 holders — while 102 added to existing stakes and 77 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $160M. The largest seller was Morgan Stanley, cutting an estimated $40.5M.

  • 251 institutional investors held Vaxcyte (PCVX) as of Q1 2024, up from 223 in Q4 2023.
  • Funds reported $8.13B of Vaxcyte stock for Q1 2024, up 25% quarter-over-quarter.
  • 48 funds opened new Vaxcyte positions in Q1 2024 and 18 closed out, a net change of +30 holders.
  • The largest Vaxcyte buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $160M added.
  • The largest Vaxcyte seller in Q1 2024 was Morgan Stanley, an estimated $40.5M sold.

Based on aggregated 13F filings for Q1 2024.